10397-15-6

Basic information

• Product Name: 2,6-dichloro-N-Methyl pyriMidin-4-aMine
• Synonyms: 2,6-dichloro-N-Methyl pyriMidin-4-aMine;4,6-dichloro-N-MethylpyriMidin-2-aMine;2-PyriMidinaMine,4,6-dichloro-N-Methyl-;4,6-DICHLORO-N-METHYL-PYRIMIDINE-2-AMINE;NSC 90604;4,6-Dichloro-N-methyl-2-pyrimidinamine
• CAS NO: 10397-15-6
• Molecular Formula: C₅H₅Cl₂N₃
• Molecular Weight: 178.0193
• EINECS: -0
• Mol File: 10397-15-6.mol
• Article Data: 9

Chemical Properties

• Melting Point: 164 °C
• Boiling Point: 295.7°C at 760 mmHg
• Flash Point: 132.7°C
• Appearance: /
• Density: 1.492
• Vapor Pressure: 0.0015mmHg at 25°C
• Refractive Index: 1.619
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.45±0.25(Predicted)
• CAS DataBase Reference: 2,6-dichloro-N-Methyl pyriMidin-4-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dichloro-N-Methyl pyriMidin-4-aMine(10397-15-6)
• EPA Substance Registry System: 2,6-dichloro-N-Methyl pyriMidin-4-aMine(10397-15-6)

Safety Data

• Hazardous Substances Data: 10397-15-6(Hazardous Substances Data)

Usage

General Description

2,6-dichloro-N-methylpyrimidin-4-amine is a chemical compound with the molecular formula C5H6Cl2N2. It is an organic compound derived from pyrimidine and contains two chlorine atoms attached to the 2 and 6 positions of the pyrimidine ring, as well as a methyl group attached to the nitrogen atom at the 4 position. 2,6-dichloro-N-Methyl pyriMidin-4-aMine is commonly used in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential biological activities, including its role as a kinase inhibitor in cancer treatment. Additionally, it is used as a reagent in organic chemistry synthesis reactions due to its unique structure and properties.

InChI:InChI=1/C5H5Cl2N3/c1-8-5-9-3(6)2-4(7)10-5/h2H,1H3,(H,8,9,10)

Upstream product

• 3764-01-0 2,4,6-trichloropyrimidine 
• 64-17-5 ethanol 
• 74-89-5 methylamine 
• 959244-40-7 2-methylamino-1H-pyrimidine-4,6-dione 
• 4489-34-3 4,6-dichloro-2-(methylsulfonyl)pyrimidine 

Downstream Products

• 202467-64-9 4-amino-N-(6-chloro-2-methylaminopyrimidin-4-yl)benzenesulfonamide 
• 1227911-44-5 (3S,6R)-1-[6-(4-cyano-3-fluorophenyl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide 
• 1227917-77-2 C₁₈H₂₀FN₅O₂ 
• 1227917-79-4 C₁₈H₁₈FN₅O₃ 
• 1227917-82-9 C₂₄H₂₉FN₆O₂ 
• 1227911-42-3 (3S,6R)-1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-6-methyl-N-phenyl-3-piperidinecarboxamide 
• 1227911-37-6 (3S,6R)-1-[6-chloro-2-(methylamino)-4-pyrimidinyl]-6-methyl-N-phenyl-3-piperidinecarboxamide 
• 1227911-45-6 GKS2334470 
• 1227911-43-4 (3S,6R)-1-[6-chloro-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-6-methyl-3-piperidinecarboxamide 
• 1227917-83-0 (2S,5R)-4-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)-4-pyrimidinyl]-N-cyclohexyl-5-methyl-2-morpholinecarboxamide 

Relevant articles and documents

Substituted pyridine and pyrimidine derivatives and their use in treating viral infections

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

CHEMICAL COMPOUNDS

The invention is directed to 6-(4-pyι?midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

NOVEL SEH INHIBITORS AND THEIR USE

The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.